{
    "xml": "<topic id=\"PHP4543\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/cyproterone-acetate\" basename=\"cyproterone-acetate\" title=\"CYPROTERONE ACETATE\">\n<title>CYPROTERONE ACETATE</title>\n<body>\n<data name=\"vtmid\">96370002</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_677939183\" title=\"Anti-androgens\">Anti-androgens</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n<data name=\"secondaryDomainsOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\n</body>\n<topic id=\"PHP43612\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/cyproterone-acetate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hypersexuality</p>\n<p outputclass=\"therapeuticIndication\">Sexual deviation</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult male\">\n<p>Adult (male)</p>\n<p>50&#8239;mg twice daily, to be taken after food.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prevention of tumour flare with initial gonadorelin analogue therapy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult male\">\n<p>Adult (male)</p>\n<p>200&#8239;mg daily in 2&#8211;3 divided doses for 5&#8211;7 days before initiation of gonadorelin analogue, followed by 200&#8239;mg daily in 2&#8211;3 divided doses for 3&#8211;4 weeks after initiation of gonadorelin analogue; maximum 300&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where oral therapy preferred</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult male\">\n<p>Adult (male)</p>\n<p>200&#8211;300&#8239;mg daily in 2&#8211;3 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Hot flushes with gonadorelin analogue therapy or after orchidectomy</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult male\">\n<p>Adult (male)</p>\n<p>Initially 50&#8239;mg daily, then adjusted according to response to 50&#8211;150&#8239;mg daily in 1&#8211;3 divided doses.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43673\" outputclass=\"contraindications\" rev=\"1.21\" parent=\"/drugs/cyproterone-acetate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">In hypersexuality, Dubin-Johnson syndrome</ph>; <ph outputclass=\"contraindication\">in hypersexuality, history of thromboembolic disorders</ph>; <ph outputclass=\"contraindication\">in hypersexuality, liver-disease</ph>; <ph outputclass=\"contraindication\">in hypersexuality, malignant diseases</ph>; <ph outputclass=\"contraindication\">in hypersexuality, previous or existing liver tumours</ph>; <ph outputclass=\"contraindication\">in hypersexuality, Rotor syndrome</ph>; <ph outputclass=\"contraindication\">in hypersexuality, severe depression</ph>; <ph outputclass=\"contraindication\">in hypersexuality, severe diabetes (with vascular changes)</ph>; <ph outputclass=\"contraindication\">in hypersexuality, sickle-cell anaemia</ph>; <ph outputclass=\"contraindication\">in hypersexuality, wasting diseases</ph>; <ph outputclass=\"contraindication\">meningioma or history of meningioma</ph>; <ph outputclass=\"contraindication\">youths under 18 years (may arrest bone maturation and testicular development)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43706\" outputclass=\"cautions\" rev=\"1.21\" parent=\"/drugs/cyproterone-acetate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Diabetes mellitus</ph>; <ph outputclass=\"caution\">in prostate cancer, severe depression</ph>; <ph outputclass=\"caution\">in prostate cancer, sickle-cell anaemia</ph>; <ph outputclass=\"caution\">ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43557\" outputclass=\"sideEffects\" rev=\"1.23\" parent=\"/drugs/cyproterone-acetate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Hypersensitivity reactions</ph>; <ph outputclass=\"sideEffect\">osteoporosis</ph>; <ph outputclass=\"sideEffect\">rash</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Breathlessness</ph>; <ph outputclass=\"sideEffect\">changes in hair pattern</ph>; <ph outputclass=\"sideEffect\">fatigue</ph>; <ph outputclass=\"sideEffect\">gynaecomastia (rarely leading to galactorrhoea and benign breast nodules)</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hepatitis</ph>; <ph outputclass=\"sideEffect\">hepatotoxicity</ph>; <ph outputclass=\"sideEffect\">inhibition of spermatogenesis</ph>; <ph outputclass=\"sideEffect\">jaundice</ph>; <ph outputclass=\"sideEffect\">lassitude</ph>; <ph outputclass=\"sideEffect\">reduced sebum production (may clear acne)</ph>; <ph outputclass=\"sideEffect\">risk of recurrence of thromboembolic disease</ph>; <ph outputclass=\"sideEffect\">weight changes</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Hepatotoxicity</p>\n<p>Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported, usually after several months, at dosages of 100&#8239;mg and above). If hepatotoxicity is confirmed, cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43627\" outputclass=\"hepaticImpairment\" parent=\"/drugs/cyproterone-acetate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid (unless used for prostate cancer)&#8212;dose-related toxicity.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43520\" outputclass=\"monitoringRequirements\" parent=\"/drugs/cyproterone-acetate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Monitor blood counts initially and throughout treatment.</p>\n<p>Monitor adrenocortical function regularly.</p>\n</sectiondiv>\n<sectiondiv>\n<p>Monitor hepatic function regularly&#8212;liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP43598\" outputclass=\"patientAndCarerAdvice\" rev=\"1.14\" parent=\"/drugs/cyproterone-acetate\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"adviceAroundDrivingAndOtherTasks\">\n<title>Driving and skilled tasks</title>\n<sectiondiv>\n<p>Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP4543-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/cyproterone-acetate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension, tablet, capsule</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75329\" title=\"Tablet\" namespace=\"/drugs/cyproterone-acetate/tablet\">Tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78568\" namespace=\"/treatment-summaries/androgens-anti-androgens-and-anabolic-steroids\" title=\"Androgens, anti-androgens and anabolic steroids\" count=\"2\" rel=\"backlink\">Androgens, anti-androgens and anabolic steroids</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78591\" namespace=\"/treatment-summaries/hormones-malignant-disease\" title=\"Hormones, malignant disease\" count=\"2\" rel=\"backlink\">Hormones, malignant disease</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75329\" namespace=\"/drugs/cyproterone-acetate/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n</links>\n</topic>",
    "id": "PHP4543",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/cyproterone-acetate",
    "basename": "cyproterone-acetate",
    "title": "CYPROTERONE ACETATE",
    "vtmid": "96370002",
    "drugClassification": [
        "Anti-androgens"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "secondaryDomainsOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Hypersexuality",
                        "html": "Hypersexuality"
                    },
                    {
                        "textContent": "Sexual deviation",
                        "html": "Sexual deviation"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult male": [
                    {
                        "textContent": "50 mg twice daily, to be taken after food.",
                        "html": "<p>50&#8239;mg twice daily, to be taken after food.</p>",
                        "ageGroup": "adult (male)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prevention of tumour flare with initial gonadorelin analogue therapy",
                        "html": "Prevention of tumour flare with initial gonadorelin analogue therapy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult male": [
                    {
                        "textContent": "200 mg daily in 2&#8211;3 divided doses for 5&#8211;7 days before initiation of gonadorelin analogue, followed by 200 mg daily in 2&#8211;3 divided doses for 3&#8211;4 weeks after initiation of gonadorelin analogue; maximum 300 mg per day.",
                        "html": "<p>200&#8239;mg daily in 2&#8211;3 divided doses for 5&#8211;7 days before initiation of gonadorelin analogue, followed by 200&#8239;mg daily in 2&#8211;3 divided doses for 3&#8211;4 weeks after initiation of gonadorelin analogue; maximum 300&#8239;mg per day.</p>",
                        "ageGroup": "adult (male)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where oral therapy preferred",
                        "html": "Long-term palliative therapy where gonadorelin analogues or orchidectomy contra-indicated, not tolerated, or where oral therapy preferred"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult male": [
                    {
                        "textContent": "200&#8211;300 mg daily in 2&#8211;3 divided doses.",
                        "html": "<p>200&#8211;300&#8239;mg daily in 2&#8211;3 divided doses.</p>",
                        "ageGroup": "adult (male)"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Hot flushes with gonadorelin analogue therapy or after orchidectomy",
                        "html": "Hot flushes with gonadorelin analogue therapy or after orchidectomy"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult male": [
                    {
                        "textContent": "Initially 50 mg daily, then adjusted according to response to 50&#8211;150 mg daily in 1&#8211;3 divided doses.",
                        "html": "<p>Initially 50&#8239;mg daily, then adjusted according to response to 50&#8211;150&#8239;mg daily in 1&#8211;3 divided doses.</p>",
                        "ageGroup": "adult (male)"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "In hypersexuality, Dubin-Johnson syndrome",
                "html": "In hypersexuality, Dubin-Johnson syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, history of thromboembolic disorders",
                "html": "in hypersexuality, history of thromboembolic disorders"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, liver-disease",
                "html": "in hypersexuality, liver-disease"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, malignant diseases",
                "html": "in hypersexuality, malignant diseases"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, previous or existing liver tumours",
                "html": "in hypersexuality, previous or existing liver tumours"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, Rotor syndrome",
                "html": "in hypersexuality, Rotor syndrome"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, severe depression",
                "html": "in hypersexuality, severe depression"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, severe diabetes (with vascular changes)",
                "html": "in hypersexuality, severe diabetes (with vascular changes)"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, sickle-cell anaemia",
                "html": "in hypersexuality, sickle-cell anaemia"
            },
            {
                "type": "contraindications",
                "textContent": "in hypersexuality, wasting diseases",
                "html": "in hypersexuality, wasting diseases"
            },
            {
                "type": "contraindications",
                "textContent": "meningioma or history of meningioma",
                "html": "meningioma or history of meningioma"
            },
            {
                "type": "contraindications",
                "textContent": "youths under 18 years (may arrest bone maturation and testicular development)",
                "html": "youths under 18 years (may arrest bone maturation and testicular development)"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Diabetes mellitus",
                "html": "Diabetes mellitus"
            },
            {
                "type": "cautions",
                "textContent": "in prostate cancer, severe depression",
                "html": "in prostate cancer, severe depression"
            },
            {
                "type": "cautions",
                "textContent": "in prostate cancer, sickle-cell anaemia",
                "html": "in prostate cancer, sickle-cell anaemia"
            },
            {
                "type": "cautions",
                "textContent": "ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)",
                "html": "ineffective for male hypersexuality in chronic alcoholism (relevance to prostate cancer not known)"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Hypersensitivity reactions",
                        "html": "Hypersensitivity reactions",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "osteoporosis",
                        "html": "osteoporosis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    },
                    {
                        "type": "rare",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Breathlessness",
                        "html": "Breathlessness",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "changes in hair pattern",
                        "html": "changes in hair pattern",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "fatigue",
                        "html": "fatigue",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "gynaecomastia (rarely leading to galactorrhoea and benign breast nodules)",
                        "html": "gynaecomastia (rarely leading to galactorrhoea and benign breast nodules)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatitis",
                        "html": "hepatitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "hepatotoxicity",
                        "html": "hepatotoxicity",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "inhibition of spermatogenesis",
                        "html": "inhibition of spermatogenesis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "jaundice",
                        "html": "jaundice",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "lassitude",
                        "html": "lassitude",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "reduced sebum production (may clear acne)",
                        "html": "reduced sebum production (may clear acne)",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "risk of recurrence of thromboembolic disease",
                        "html": "risk of recurrence of thromboembolic disease",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "weight changes",
                        "html": "weight changes",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Hepatotoxicity",
                "textContent": "Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported, usually after several months, at dosages of 100 mg and above). If hepatotoxicity is confirmed, cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk).",
                "html": "<p>Direct hepatic toxicity including jaundice, hepatitis and hepatic failure have been reported (fatalities reported, usually after several months, at dosages of 100&#8239;mg and above). If hepatotoxicity is confirmed, cyproterone should normally be withdrawn unless the hepatotoxicity can be explained by another cause such as metastatic disease (in which case cyproterone should be continued only if the perceived benefit exceeds the risk).</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid (unless used for prostate cancer)&#8212;dose-related toxicity.",
                "html": "<p>Avoid (unless used for prostate cancer)&#8212;dose-related toxicity.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Monitor blood counts initially and throughout treatment.\n\nMonitor adrenocortical function regularly.",
                "html": "<p>Monitor blood counts initially and throughout treatment.</p><p>Monitor adrenocortical function regularly.</p>"
            },
            {
                "type": "patientParameters",
                "textContent": "Monitor hepatic function regularly&#8212;liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur.",
                "html": "<p>Monitor hepatic function regularly&#8212;liver function tests should be performed before and regularly during treatment and whenever symptoms suggestive of hepatotoxicity occur.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "adviceAroundDrivingAndOtherTasks": [
            {
                "type": "adviceAroundDrivingAndOtherTasks",
                "textContent": "Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).",
                "html": "<p>Fatigue and lassitude may impair performance of skilled tasks (e.g. driving).</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension",
                "tablet",
                "capsule"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75329",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78568",
                "label": "Androgens, anti-androgens and anabolic steroids",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78591",
                "label": "Hormones, malignant disease",
                "type": "treatmentSummary"
            }
        ]
    },
    "links": {
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75329",
                "label": "Tablet",
                "type": "medicinalForm"
            }
        ]
    }
}